Research
Feverfew
18 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Feverfew for preventing migraine.
Systematic review of five double-blind RCTs with 343 patients assessing the efficacy and safety of feverfew for preventing migraine. Results were mixed and did not convincingly establish efficacy over placebo. Only mild and transient adverse events were reported.
Feverfew for migraine prophylaxis: a systematic review.
Systematic review of randomized controlled trials on feverfew for migraine prophylaxis. The review suggests benefit of feverfew in migraine prevention for some populations, but highlights potential concerns with long-term dosing due to cyclooxygenase-2 inhibiting effects.
The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review.
Systematic review of randomized, placebo-controlled, double-blind trials assessing feverfew for migraine prevention. The majority of trials favor feverfew over placebo, with mild and transient adverse effects reported.
Feverfew for preventing migraine.
Systematic review of randomized, placebo-controlled, double-blind trials assessing feverfew for migraine prevention. Majority of trials suggested beneficial effects, but the largest and highest quality trial found no significant difference between feverfew and placebo.
Comparison of the Effect of Tanacethum Parthenium, 5-Hydroxy Tryptophan, and Magnesium (Aurastop) versus Magnesium Alone on Aura Phenomenon and Its Evolution.
Pilot clinical trial comparing Aurastop (a combination of tanacetum parthenium, 5-hydroxy tryptophan, and magnesium) with magnesium alone in treating acute migraine with aura. Aurastop significantly reduced aura duration and aura-related disability compared to magnesium alone, and reduced the need for painkillers during aura attacks.
The combined effect of acupuncture and Tanacetum parthenium on quality of life in women with headache: randomised study.
Randomized study of 69 women with chronic migraine comparing acupuncture, Tanacetum parthenium, and their combination. The combination treatment was more effective in improving quality of life, reducing migraine disability, and decreasing pain scores compared to either treatment alone.
A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine.
A double-blind placebo-controlled pilot study evaluated sublingual feverfew/ginger in 60 patients treating 221 migraine attacks. Feverfew/ginger showed significant pain relief compared to placebo, with 32% of subjects pain-free at 2 hours versus 16% for placebo. Feverfew/ginger was generally well tolerated.
Anti-inflammatory activity of parthenolide-depleted Feverfew (Tanacetum parthenium).
The study developed a parthenolide-depleted extract of Feverfew (PD-Feverfew) to reduce skin sensitization risk and evaluated its anti-inflammatory effectiveness. PD-Feverfew inhibited pro-inflammatory enzymes and mediators, reduced dermatitis in vivo, and decreased erythema in a clinical model, demonstrating potent anti-inflammatory activity.
Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study.
RCT investigating the efficacy and tolerability of a CO2-extract of feverfew (MIG-99, 6.25 mg t.i.d.) for migraine prevention in 170 patients. The migraine frequency decreased significantly in the MIG-99 group compared to placebo, with a favourable benefit-risk ratio.
Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer.
Phase I trial evaluating the pharmacokinetics and toxicity of parthenolide in feverfew for cancer patients. Feverfew was administered as a daily oral tablet with dose escalations up to 4 mg. No significant toxicity was observed, but parthenolide plasma concentrations were not detectable.
The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.
This double-blind, multicentre, randomized placebo-controlled study evaluated the efficacy and safety of Tanacetum parthenium (feverfew) extract MIG-99 in migraine prophylaxis. The study found no significant overall effect on migraine frequency, but a dose-dependent decrease in attacks was observed in a small subgroup of patients with frequent migraines. Adverse events were similar across treatment and placebo groups.
Feverfew as a preventive treatment for migraine: a systematic review.
Systematic review of randomized, placebo-controlled, double-blind trials evaluating feverfew for migraine prevention. Five trials were included, with the majority favoring feverfew over placebo, but the clinical effectiveness remains unestablished beyond reasonable doubt.
Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase.
Open-label study of GelStat Migraine, a combination of feverfew and ginger, in 30 subjects with migraines. 48% were pain-free two hours after treatment during the mild pain phase, with minimal side effects. GelStat Migraine was effective as a first-line abortive treatment for migraines.
Randomised double-blind placebo-controlled trial of feverfew in migraine prevention.
Randomised, double-blind, placebo-controlled crossover study assessing feverfew for migraine prophylaxis in 72 volunteers. Feverfew treatment reduced the mean number and severity of migraine attacks and vomiting, with significant improvement in visual analogue scores. No serious side-effects were reported.
[Feverfew as a prophylactic treatment of migraine].
Study on the efficacy of feverfew in migraine treatment with 24 female patients aged 19-61. Feverfew was administered once daily for 30-60 days, resulting in a significant reduction of Migraine Index in 8 patients and less significant reduction in 5 additional patients. The study suggests feverfew may be beneficial in migraine prophylaxis.
Feverfew in rheumatoid arthritis: a double blind, placebo controlled study.
Double-blind, placebo-controlled RCT of 41 female patients with rheumatoid arthritis receiving dried chopped feverfew or placebo for six weeks. No important differences in clinical or laboratory variables were observed, indicating no apparent benefit from oral feverfew in rheumatoid arthritis.
Efficacy of feverfew as prophylactic treatment of migraine.
Double blind placebo controlled trial with 17 migraine patients using feverfew as prophylaxis. Patients receiving placebo experienced increased frequency and severity of migraine symptoms, while those taking feverfew showed no change, suggesting feverfew's efficacy in preventing migraine attacks.
Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study.
Prospective, open-label study of 12 patients with migraine treated with Mig-RL (Tanacetum parthenium and Salix alba combination) for 12 weeks. Mig-RL reduced migraine attack frequency, intensity, and duration significantly, with improvements in general health and no adverse events.